SMS Pharmaceuticals has announced its audited financial results for the fourth quarter and fiscal year ended March 31, 2026. The company reported a standalone net profit of ₹2,092.09 lakh for the quarter ended March 31, 2026, compared to ₹2,062.24 lakh in the same period last year. For the full fiscal year 2025-26, the standalone net profit increased to ₹8,760.93 lakh from ₹6,838.12 lakh in the previous year, marking a significant growth in annual earnings.

Financial Performance

The company's revenue from operations for the fiscal year stood at ₹88,687.10 lakh, up from ₹78,274.81 lakh in FY2024-25. Total income for the year rose to ₹89,522.48 lakh. The board has recommended a final dividend of ₹0.40 per equity share (40%) of face value ₹1 each for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting.

Q4 Performance

For the fourth quarter, SMS Pharmaceuticals reported revenue of ₹23,794.75 lakh compared to ₹24,819.56 lakh in the same period last year. Q4 EBITDA came in at ₹2,704.56 lakh versus ₹2,906.44 lakh year-on-year. Standalone net profit for Q4 stood at ₹2,092.09 lakh against ₹2,062.24 lakh in the corresponding quarter of the previous year.

Corporate Developments

During the board meeting held on May 22, 2026, the directors approved the shifting of the registered office from Plot No. 72, Banjara Hills, to 8th Floor, Trendset Jayabheri Connect, Kondapur, Hyderabad, effective May 25, 2026. Additionally, the board appointed M/s. Annapragada & Co. as Cost Auditors and re-appointed M/s. Adusumilli & Associates as Internal Auditors for the financial year 2026-27. The statutory auditors, M/s. Suryanarayana & Suresh, issued an unmodified opinion on the audited financial statements.

SMS Pharmaceuticals Limited has initiated the Investor Education and Protection Fund Authority's (IEPFA) "Second 100 Days Campaign- Saksham Niveshak" as part of its compliance and investor protection efforts. The campaign, which runs from April 1, 2026, to July 9, 2026, aims to reach out to shareholders who have not claimed their dividends or need to update their Know Your Customer (KYC) details.

The company has published newspaper advertisements in The Financial Express (English) and Nava Telangana (Telugu) to inform shareholders about this initiative. The campaign specifically targets shareholders with issues related to unclaimed dividends and shares, encouraging them to take necessary action to prevent their dividends and shares from being transferred to the IEPFA.

Campaign Objectives and Shareholder Action

The primary objective of the Saksham Niveshak campaign is to assist shareholders in updating their essential details and claiming their rightful dues. Shareholders are requested to update the following information:

• KYC requirements
• Bank mandates
• Nominee details
• Contact information

Shareholders who hold shares in demat form are advised to approach their Depository Participants where they maintain their demat accounts for updating their KYC requirements. Those with physical share holdings or other queries can contact the company's Registrar and Transfer Agent.

Contact Information for Shareholders

Shareholders requiring assistance or wishing to claim unclaimed dividends and update their details can reach out to the designated authorities:

The information regarding the campaign has been uploaded on SMS Pharmaceuticals Limited 's website at www.smspharma.com , ensuring easy access for all stakeholders.

Company Details

SMS Pharmaceuticals Limited, with its registered and corporate office located at Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad - 500 034, Telangana, operates under the Corporate Identity Number L24239TG1987PLC008066. The company's shares are listed on BSE Limited with the security code 532815 and trading symbol SMSPHARMA.

Thirumalesh Tumma, Company Secretary & Compliance Officer of SMS Pharmaceuticals Limited, issued the notice on behalf of the Board of Directors, emphasizing the company's commitment to investor education and protection.